metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
hepatocell cancer (HCC) hepatocell cancer (HCC)
versus Standard of Care (SoC)
	sintilimab
	Wang, 2024 Nat Med 2024; 30:708-715-. ChiCTR2000037655	RCT	hepatocell cancer (HCC), mHCC - (neo)adjuvant (NA)	sintilimab	SOc		99 / 99	NA	conclusif	demonstrated 47 % decrease in RFS/DFS (PE) statistically significant 200.0-fold increase in AE (any grade) statistically significant 26.2-fold increase in AE (grade 3-4)
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus Standard of Care (SoC)
	sintilimab
	Wang, 2024 Nat Med 2024; 30:708-715-. ChiCTR2000037655	RCT	hepatocell cancer (HCC), mHCC - (neo)adjuvant (NA)	sintilimab	SOc		99 / 99	NA	conclusif	demonstrated 47 % decrease in RFS/DFS (PE) statistically significant 200.0-fold increase in AE (any grade) statistically significant 26.2-fold increase in AE (grade 3-4)
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	sintilimab
	ORIENT-32, 2021 NCT03794440	RCT	mHCC - 1st line (L1)	Sintilimab plus IBI305 (bevaciumab biosimilar)	Sorafenib	patients with unresectable, locally advanced, or metastatic hepato cellular carcinoma, with a diagnosis that was histologically, cytologically, or clinically confirmed, who had received no previous systemic therapy for advanced or metastatic disease, or were unsuitable for radical surgery or had local treatment stage B	380 / 191	low	conclusif	demonstrated 43 % decrease in deaths (OS) (PE)